Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.
Status:
Completed
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase IV, single site, randomized, open-label, parallel study comparing
BYDUREON-BCise plus FARXIGA to BYDUREON-BCise alone and FARXIGA alone in patients diagnosed
with Type 2 Diabetes Mellitus (T2DM) on a stable dose of metformin alone.